Neuramis Deep with Lidocaine

Neuramis Deep with Lidocaine: High-Strength Volumizing Filler with Integrated Anesthetic for Deep Structural Rejuvenation

Neuramis Deep with Lidocaine, manufactured by **LG Chem Life Sciences**, is a **premium, monophasic, non-animal stabilized hyaluronic acid (NASHA) dermal filler** designed for **profound structural volumization and lifting**, featuring **integrated 0.3% lidocaine** for enhanced patient comfort. Presented in a **1.0 ml prefilled syringe**, it utilizes a **high concentration (23 mg/ml) of cross-linked HA** to restore significant volume deficits and provide strong projection in deep facial contours. Its high elasticity and cohesivity make it ideal for lifting sagging tissues and redefining facial architecture, while the lidocaine minimizes procedural discomfort.https://skin-reboot.com/

**Core Technology & Properties:**
* **Premixed Monophasic NASHA Gel:** Homogeneous, highly cross-linked (BDDE) HA matrix ensures predictable tissue integration, stability, and smooth flow.
* **Integrated 0.3% Lidocaine:** Provides immediate local anesthesia during injection, significantly improving patient comfort and tolerance.
* **High G-Prime (Elasticity):** Delivers **exceptional resistance to deformation**, enabling powerful lifting of tissues and maintaining projection against gravity in deep planes.
* **High Cohesivity:** Gel particles bind tightly, ensuring **strong structural integrity**, minimizing spread/migration, and maximizing lifting capacity.
* **High HA Concentration (23 mg/ml):** Provides significant volumizing power per injection for substantial restoration.
* **Optimized Particle Size:** Engineered for durability and performance in deep subcutaneous and supraperiosteal layers.

**Mechanism of Action:**
1. **Structural Volumization & Lift:** High-cohesivity gel creates immediate projection and lift upon deep injection, restoring volume and recontouring sagging areas.
2. **Hydration:** HA binds water, improving tissue hydration.
3. **Biostimulation:** Stimulates gradual collagen and elastin production for sustained tissue improvement.
4. **Anesthesia:** Lidocaine blocks local nerve signals, reducing injection pain.

**Primary Indications:**
* **Midface Volumization & Lift:** Augmenting cheekbones, restoring malar volume, lifting nasolabial folds.
* **Jawline Definition & Contouring:** Enhancing mandibular projection and angle.
* **Chin Augmentation:** Adding anterior projection and improving profile.
* **Temporal Hollowing:** Restoring volume to sunken temples.
* **Deep Nasolabial Folds & Marionette Lines:** Correcting severe perioral folds requiring structural support.
* **Facial Rebalancing & Projection:** Enhancing overall facial harmony and profile aesthetics.

**Key Administration Considerations:**
* **Ready-to-Use:** No reconstitution required. Prime syringe carefully.
* **Anesthesia:** Integrated lidocaine provides core comfort; adjunctive topical numbing cream may still be used for sensitive patients/areas.
* **Technique:** Primarily suited for **bolus/depot placement**:
* **Needles:** Sharp needles (e.g., 25-27G) for precise supraperiosteal injection.
* **Cannulas:** Highly compatible with blunt microcannulas (e.g., 22-25G, 50mm+) for deep subcutaneous/sub-SMAS placement, reducing vascular risks and bruising.
* **Depth:** **Deep subcutaneous tissue, supraperiosteal plane, or sub-SMAS layer.** *Avoid superficial injection.*
* **Volume:** Typically requires larger boluses (e.g., 0.2-0.5ml per point). Gradual build-up recommended.
* **Post-Treatment:** Expect significant **swelling** (can last several days), redness, tenderness, and potential bruising. Avoid pressure/massage on treated areas.
* **Longevity:** Designed for **long-lasting results**, typically **12-18 months**, due to high HA concentration and cross-linking density.
* **Safety:** Standard filler risks: Swelling, bruising, redness, nodules, infection, hypersensitivity (including to lidocaine). **Critical Risk:** **Vascular occlusion** is possible due to deep placement; necessitates **expert anatomical knowledge**, aspiration, and preference for cannulas. Risk of visible nodules if placed too superficially or overcorrected. Tyndall effect unlikely at correct depth.
* **Regulatory Status:** **CE marked** (Europe/international). **Not FDA-approved in the USA.**
* **Prescription:** Prescription medical device.

Neuramis Deep with Lidocaine combines potent deep-tissue volumization and lift with integrated anesthetic, offering practitioners an effective solution for significant structural facial restoration while optimizing patient comfort during the procedure.CONTACT US